OnProcess and Baxter Planning Forge Strategic Product and Commercial Partnership
OnProcess Technology (www.onprocess.com), a global pioneer powering the world’s circular service supply chains, today announced the formation of a new strategic commercial and product partnership with Baxter Planning (www.baxterplanning.com). The partnership includes joint investment in the two companies’ technology roadmaps, a commitment to integrating certain product offerings, and a combined commercial approach.
The partnership is in response to what both companies see as growing industry calls to deliver and manage best-in-class service supply chains. As a result of several macroeconomic factors - global supply chain uncertainties, growing demand for sustainable practices, increasing e-waste legislation, the continued move to servitization, as well as higher cost of goods driven by rising interest rates and inflation - both companies cite that there has never been more focus on the role that the service supply chains play.
OnProcess and Baxter Planning have aligned views around the need to speed up the digitalization across the three main functions of the service supply chain:
- Planning (ensuring inventory levels are available in the right places to meet service-level commitments/SLAs)
- Delivering (ensuring inventory is delivered efficiently, to customers or other end-users, according to SLAs) and
- Recovering (ensuring that the maximum value is recovered from assets no longer required in the field, whether that inventory is unused, in need of repair/refurbishment/recycling, or for warranty recovery)
And putting Customer Experience at the heart of the service event.
The two companies recognize that to solve the complexities of the service supply chain requires a foundation built on aggregated data, and a platform that integrates and gathers that data from otherwise siloed operational sources. Only then can the three functional areas of Planning, Delivery and Recovery fully work together and provide a seamless view of the whole service supply chain. This results in smarter decisions, frictionless customer experiences, and a circular model that helps drive towards sustainability goals and targets.
With Baxter’s long-established record as a leader in the inventory planning market, and OnProcess’s reputation as a full-service provider to some of the world’s most recognised brands, the two companies have committed to further integrating their respective product offerings, such as Baxter Planning’s Prophet for service parts planning, and OnProcess’s Agora platform.
“We are excited to announce this very strategic partnership with Baxter,” said Oliver Lemanski, CEO, OnProcess. “Their deep domain expertise in service inventory planning, along with their market-leading software products, makes a natural fit with OnProcess, and in particular our technology platform Agora. We are on a mission to power the world’s circular service supply chains across a seamless process flow of Planning, Delivery and Recovery, and to do that we welcome partnerships, such as this with Baxter, to help us deliver on our promise . ”
“OnProcess has an enviable reputation in the service supply chain market, with some of the world’s most recognized brands as their clients,” stated Chuck Moeling, CEO, Baxter Planning. “As a best-of-breed planning provider, we see only synergy with OnProcess’s focus on Delivery and Recovery. We look forward to deepening our relationship and further developing our respective products so we can provide our mutual customers the very best the market has to offer . ”
About OnProcess Technology, Inc.
OnProcess supplies technology and services that power the world’s circular service supply chains. Delivering through the Agora™ platform, OnProcess streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals for many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies. For more information please visit www.onprocess.com.
About Baxter Planning
Founded in 1993, Baxter Planning was built expressly for the service supply chain. Their software is developed based on proven best practices, industry expertise, and a partnership with customers to automate inventory planning. Their Total Cost Optimization methodology replaces spreadsheets and manual processes to deliver the best service level at the lowest possible cost. As a worldwide leader in Service Supply Chain software, Baxter Planning helps customers plan billions in service parts inventory every day. For more information, visit http://www.baxterplanning.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005079/en/
Contact information
Marta Marinova
OnProcess Technology, Inc.
mmarinova@onprocess.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
